Last $1.47 USD
Change Today -0.02 / -1.34%
Volume 142.6K
ABIO On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

arca biopharma inc (ABIO) Snapshot

Open
$1.50
Previous Close
$1.49
Day High
$1.51
Day Low
$1.44
52 Week High
01/8/14 - $2.54
52 Week Low
01/22/14 - $1.19
Market Cap
30.9M
Average Volume 10 Days
334.9K
EPS TTM
$-1.13
Shares Outstanding
21.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARCA BIOPHARMA INC (ABIO)

Related News

No related news articles were found.

arca biopharma inc (ABIO) Related Businessweek News

No Related Businessweek News Found

arca biopharma inc (ABIO) Details

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

14 Employees
Last Reported Date: 03/21/14

arca biopharma inc (ABIO) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $389.4K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $338.8K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $323.6K
Compensation as of Fiscal Year 2013.

arca biopharma inc (ABIO) Key Developments

ARCA biopharma, Inc. Elects Robert E. Conway as Chairman of the Board of Directors

ARCA biopharma, Inc. announced that Robert E. Conway has been elected Chairman of the company's Board of Directors. He serves on the Audit and Compensation Committees of the Board of Directors. Mr. Conway has over 30 years of executive leadership experience in the pharmaceutical and biotechnology industries. Mr. Conway served as the Chief Executive Officer and member of the Board of Directors of Array BioPharma from 1999 to 2012. Prior to joining Array, Mr. Conway was the Chief Operating Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999.

ARCA biopharma, Inc. Announces Screening of First Patient in Phase 2B/3 Clinical Trial Evaluating Gencaro in Atrial Fibrillation

ARCA biopharma, Inc. announced that the first patient has been genetically screened in GENETIC-AF, its Phase 2B/3 adaptive design clinical trial. The GENETIC-AF trial will evaluate Gencaro(TM) (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure and/or left ventricular dysfunction who also have a specific genotype of the beta-1 adrenergic receptor (389 arginine homozygous), which is believed to be present in approximately 50% of the U.S. population. There are currently seven active clinical trial sites recruiting patients for GENETIC-AF. The Company anticipates having approximately 50 clinical trial sites for the Phase 2B portion of the trial. Last week, ARCA hosted the initial GENETIC-AF Investigator Meeting which brought together the physicians and research coordinators participating in the trial for information sharing and study-specific training. Gencaro is an investigational, pharmacologically unique beta-blocker and mild vasodilator. ARCA has identified common genetic variations that it believes may predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. Currently, no beta-blocker has been approved by the U.S. Food and Drug Administration for the prevention of AF. AF is considered an epidemic cardiovascular disease. The estimated number of individuals with AF globally in 2010 was 33.5 million. According to the 2014 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the U.S. in 2010 ranged from 2.7 to 6.1 million. AF increases the risk of stroke and may also contribute to worsening heart failure.

ARCA biopharma, Inc., Annual General Meeting, Jun 05, 2014

ARCA biopharma, Inc., Annual General Meeting, Jun 05, 2014., at 09:00 US Mountain Standard Time. Location: Denver Marriott Westminster Hotel. Agenda: To elect the board’s nominees, Dr. Michael Bristow and Mr. Robert Conway, to the board of directors to hold office until the 2017 annual meeting of stockholders; to ratify the selection by the audit committee of the board of directors of KPMG LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2014; and to conduct any other business properly brought before the meeting.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABIO:US $1.47 USD -0.02

ABIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ABIO.
View Industry Companies
 

Industry Analysis

ABIO

Industry Average

Valuation ABIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARCA BIOPHARMA INC, please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.